Elamipretide is a daily injection sold for muscle strength in Barth syndrome, a rare energy-failure condition. Without that diagnosis, the record is thin and mixed. Larger trials missed everyday-function goals. Injection-site irritation is common; allergic reactions are uncommon but documented. Research vials are not the approved product. The longevity case remains an argument about how it is thought to work. (Full Review)

Protocol

Approved Barth regimen (Forzinity)

40 mg subcutaneously once daily

Same time each day in people ≥30 kg; split dosing is not in the label

Kidney disease

20 mg daily

Adult eGFR <30 mL/min off dialysis; no reduction for mild-to-moderate impairment

Longevity-clinic cycling

Multi-week subcutaneous courses

Not trial-validated for longevity; labeled Barth use is once daily

Time to effect

Barth walk distance

Months, not days

Open-label gains accumulated over months

Muscle ATP-generating capacity

During a 2-hour infusion

Gone by day 7; no fatigue-resistance gain

Benefits

Low: Knee extensor strength in Barth syndrome; photoreceptor ellipsoid-zone preservation in dry age-related macular degeneration; visual acuity in Leber hereditary optic neuropathy; exercise capacity in primary mitochondrial myopathy

Speculative: Age-related cardiac and skeletal muscle function; muscle ATP capacity after a single infusion in older adults; general energy, recovery, and performance in healthy adults

Contraindications

Serious hypersensitivity: absolute contraindication after a severe whole-body allergic reaction

Neonates and preterm infants: not a labeled population

Severe renal impairment on dialysis: dose not established

Key Interactions

MATE1 substrates (metformin): can raise metformin exposure

Mitochondrial supplements (coenzyme Q10, L-carnitine, creatine, MitoQ): potential additive bioenergetic claims, untested as combinations

Other mitochondrial peptides (MOTS-c) and oxidant-cycling agents (methylene blue): theoretical stacking; no controlled human combination data

Oral antihistamines (cetirizine, diphenhydramine): older agents can add daytime sleepiness

Risk & Side Effects

High: Injection-site reactions

Medium: Hypersensitivity

Low: Eosinophil increases

Speculative: Blunting of adaptive mitochondrial oxidant signaling

Monitoring

Marker	Target	Why
eGFR (CKD-EPI)	≥90 mL/min/1.73 m²; dose-cut <30	Exposure and dose
Eosinophil count	Track versus personal baseline; hold if symptomatic eosinophilic disease or >1,000 cells/µL	Allergy-type inflammation
CBC with differential	Individual baseline; watch hemoglobin and white-cell pattern	Systemic reaction screen
6MWT or knee extensor strength	Change from the individual's own baseline; no established longevity target	Function that trials actually measured
Symptom fatigue score	Change from diary baseline	Subjective stamina

Cadence: Baseline before the first injection; repeat at about 4 weeks, again at 12 weeks, then every 3–6 months while injections continue

Qualitative Assessment

Energy stability across the day, not a brief post-injection lift
Injection-site comfort and absence of spreading rash or hives
Training recovery and walk or climb tolerance versus the pre-start diary
Sleep quality if antihistamines or site pain are in use

Elamipretide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment